Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
at www.tipranks.com (Wed, 22-Jul 5:35 PM)
FDA accepts Revolution Medicines' NDA for daraxonrasib for pancreatic cancer
at seekingalpha.com (Wed, 22-Jul 4:27 PM)
Revolution Medicines Outlines Leadership Transition as Dr. Steve Kelsey Plans Retirement—New Structure to Steer R&D Forward
Market Chameleon (Mon, 22-Jun 8:15 AM)
